

Published in final edited form as:

Nat Chem Biol. 2008 February ; 4(2): 97–106. doi:10.1038/nchembio.68.

Chemical approaches to understanding *O*-GlcNAc glycosylation in the brain

Jessica E Rexach^{1,2}, Peter M Clark^{1,2}, and Linda C Hsieh-Wilson¹

¹Division of Chemistry and Chemical Engineering, and Howard Hughes Medical Institute, California Institute of Technology, Pasadena, California 91125, USA

Abstract

O-GlcNAc glycosylation is a unique, dynamic form of glycosylation found on intracellular proteins of all multicellular organisms. Studies suggest that *O*-GlcNAc represents a key regulatory modification in the brain, contributing to transcriptional regulation, neuronal communication and neurodegenerative disease. Recently, several new chemical tools have been developed to detect and study the modification, including chemoenzymatic tagging methods, quantitative proteomics strategies and small-molecule inhibitors of *O*-GlcNAc enzymes. Here we highlight some of the emerging roles for *O*-GlcNAc in the nervous system and describe how chemical tools have significantly advanced our understanding of the scope, functional significance and cellular dynamics of this modification.

O-GlcNAc glycosylation, the covalent attachment of β -*N*-acetylglucosamine to serine or threonine residues of proteins, is an unusual form of protein glycosylation¹ (Fig. 1). Unlike other types of glycosylation, this single-sugar modification occurs on intracellular proteins and is not elaborated further into complex glycans. The *O*-GlcNAc transferase (OGT) enzyme is a soluble protein that is found in the cytosol, nucleus and mitochondria², rather than in the endoplasmic reticulum or Golgi. The dynamics of *O*-GlcNAc are also unique among sugar modifications, being cycled on a shorter time scale than protein turnover³. Thus, in many respects *O*-GlcNAc is more akin to phosphorylation than to conventional forms of glycosylation.

Several reviews have described the roles of *O*-GlcNAc in cellular processes, such as transcription^{2,4}, the stress response^{5,6}, apoptosis^{7,8}, signal transduction^{2,9}, glucose sensing^{5,10} and proteasomal degradation⁵. Only a few reviews have highlighted the importance of *O*-GlcNAc glycosylation in the nervous system, and those reports have focused on its potential impact on neurodegenerative diseases^{11,12}. However, several lines of evidence suggest that *O*-GlcNAc has crucial roles in both neuronal function and dysfunction. The enzymes responsible for the modification are most highly expressed in the brain^{13,14} and are enriched at neuronal synapses^{15,16}. Neuron-specific deletion of the OGT gene in mice leads to abnormal development and locomotor defects, resulting in neonatal death¹⁷. The *O*-GlcNAc modification is abundant in the brain and present on many proteins important for transcription, neuronal signaling and synaptic plasticity, such as cAMP-responsive element binding protein (CREB)¹⁸, synaptic Ras GTPase-activating protein (synGAP)¹⁹ and β -amyloid precursor protein (APP)²⁰. An intriguing interplay between *O*-GlcNAc glycosylation and phosphorylation has been observed in cerebellar neurons, wherein activation of certain kinase pathways reduces *O*-GlcNAc levels on cytoskeleton-

associated proteins²¹. Finally, recent studies suggest that *O*-GlcNAc is dynamically regulated by excitatory stimulation of the brain *in vivo*¹⁹.

Over the past 5 years, new chemical approaches have been developed to meet the specific challenges associated with studying *O*-GlcNAc glycosylation in the brain. Methods for chemically tagging and identifying *O*-GlcNAc-glycosylated proteins have vastly expanded the number of neuronal proteins known to be *O*-GlcNAc modified. New pharmacological inhibitors of the *O*-GlcNAc enzymes have been discovered that may overcome some of the limitations of genetic approaches. Quantitative proteomics strategies designed to accommodate postmitotic neurons and brain tissue have been used to monitor changes in glycosylation levels in response to neuronal stimuli. Combined with recent advances in mass spectrometry, these powerful tools have provided an unprecedented opportunity to explore the *O*-GlcNAc proteome, manipulate glycosylation levels and study the dynamics of this modification *in vivo*.

In this Review, we describe emerging functions for *O*-GlcNAc glycosylation in the nervous system. We then consider the modification in the context of chemical biology, describing chemical approaches that have accelerated an understanding of *O*-GlcNAc and chemical tools needed to further advance the field.

The enzymes OGT and OGA

OGT and β -*N*-acetylglucosaminidase (OGA or *O*-GlcNAcase) catalyze the reversible addition and removal of *O*-GlcNAc, respectively. Both enzymes are most highly expressed in the brain and exist as several different isoforms^{2,22}. Three distinct isoforms of OGT have been identified, including a 110-kDa and a 78-kDa isoform, which can assemble into multimers^{23,24}, and a smaller mitochondrial isoform. Each variant contains a C-terminal catalytic domain, but differs in the number of tetratricopeptide repeats (TPRs) within its N-terminal domain. The TPRs serve as protein-protein interaction modules that appear to target OGT to accessory proteins and potential substrates, such as the GABA_A receptor interacting factor-1 (GRIF-1)²⁵ and the related *O*-GlcNAc transferase interacting protein (OIP106)²⁵, which have been implicated in mitochondrial trafficking to synapses^{26,27}, and the transcriptional repressor complex mSin3A–histone deacetylase 1 (HDAC1)²⁸. In addition, OGT forms a complex with protein phosphatase-1 (PP1) in the brain²⁹. The association between OGT and PP1 is particularly intriguing, as it may provide a direct mechanism to couple *O*-GlcNAc glycosylation to dephosphorylation of specific substrates. Although OGT is found in the nucleus, cytosol and mitochondria, it is particularly enriched in the nucleus¹⁵ and the soluble synaptic compartment¹⁶.

Like OGT, OGA seems to be highly active at neuronal synapses¹⁶, and it is also found in the nucleus and cytosol³⁰. OGA contains an N-terminal glycosidase domain and a putative C-terminal histone acetyltransferase (HAT) domain³¹. Two distinct isoforms of OGA exist, a 130-kDa and a 75-kDa variant, which share the same catalytic domain but differ in their C terminus³². The potential HAT activity of OGA may provide an interesting mechanism for coupling deglycosylation of nuclear proteins to transcriptional activation. As with OGT, OGA has been shown to interact with specific proteins, including calcineurin (also known as protein phosphatase-2B), amphiphysin and dihydropyrimidinase-related protein 2 (DRP2, also known as CRMP1)³⁰.

Transcriptional regulation

Early studies revealed that the *O*-GlcNAc modification is enriched on chromatin³³ and is found on RNA polymerase II and many of its transcription factors³⁴. As described in several reviews^{2,4,35}, *O*-GlcNAc glycosylation has been shown to both enhance and suppress the

activity of transcription factors. *O*-GlcNAc can disrupt protein-protein interactions, as in the case of Sp1, whose glycosylation represses transcription at Sp1-driven promoters^{36,37}. In other cases, it can promote protein-protein interactions, as in the case of signal transducer and activator of transcription 5A (STAT5A), whose glycosylation enhances its activity by recruiting the transcriptional coactivator CREB-binding protein (CBP)³⁸. *O*-GlcNAc may also play a more general role in transcriptional repression through a mechanism involving the targeting of OGT to an HDAC1 complex by the corepressor mSin3A²⁸. In addition to altering protein-protein interactions, *O*-GlcNAc can affect post-translational modifications. For instance, glycosylation stabilized the tumor suppressor protein p53 by decreasing its phosphorylation and subsequent degradation by the proteasome³⁹.

Much less is known about the transcriptional roles of *O*-GlcNAc in the brain. However, CREB, a transcription factor important for neuronal survival, long-term memory storage and drug addiction^{40,41}, was shown to be *O*-GlcNAc glycosylated in the rodent brain¹⁸. Glycosylation occurred at two major sites within the Q2 transactivation domain of CREB and disrupted binding of CREB to TAF_{II}130, a component of the basal transcriptional machinery. As a result, glycosylation repressed the transcription of CRE-mediated genes both *in vitro* and in cells¹⁸. It will be interesting to investigate whether glycosylation of CREB is dynamically regulated in neurons, and whether it downregulates specific genes associated with memory storage and cell survival.

Early growth response-1 (EGR1), a transcription factor important for neuronal survival and long-term memory storage^{42,43}, was also recently shown to be *O*-GlcNAc modified in the brain¹⁹. Notably, glycosylation of EGR1 was found to be dynamically modulated by excitatory stimulation of the brain *in vivo*. Stimulation of rats with the glutamate receptor agonist kainic acid led to a ten-fold increase in glycosylation of EGR1 within its transactivation domain¹⁹. Although the functional implications of this response will require further investigation, these studies raise the exciting possibility that neuronal activity regulates the transcriptional activity of EGR1 by modulating EGR1 glycosylation levels.

Proteomic studies of *O*-GlcNAc-modified proteins from the brain have also underscored the importance of *O*-GlcNAc in regulating transcription. Approximately one-quarter of the neuronal *O*-GlcNAc-modified proteins known to date are transcriptional regulatory proteins^{19,44} (Fig. 2). This includes numerous transcription factors (for example, SRY box-containing gene 2 (SOX2), activating transcription factor 2 (ATF2) and EGR1), as well as transcriptional coactivators (steroid receptor coactivator-1 (SRC1)), repressors (p66 β and BRAF-HDAC complex 80 (BHC80)) and corepressors (transducin-like enhancer of split 4 (TLE4), carbon catabolite repression 4-negative on TATA-less (CCR4-NOT)). For instance, SOX2 is a member of the high-mobility group box (HMG) superfamily of minor groove DNA binding proteins, and it functions to regulate transcription on different promoters depending on its interactions with specific protein partners⁴⁵. SOX2 interacts with proteins through its highly conserved HMG DNA binding domain, which also contains its *O*-GlcNAc modification site⁴⁴. One of the well-established functions of SOX2 is its crucial role in the maintenance of embryonic stem cell pluripotency in partnership with OCT4 (also known as POU5F1)⁴⁶. In the adult rat brain, SOX2 expression has been reported to occur in actively dividing adult neuronal precursor cells and in neurogenic astroglia⁴⁷. Another example of the expanding role of *O*-GlcNAc in transcription is the modification of two proteins (including a ubiquitin ligase) in CCR4-NOT⁴⁴, a large protein complex involved in mRNA metabolism and in the global control of gene expression⁴⁸. Together with earlier studies demonstrating glycosylation of RNA polymerase II, these findings suggest that *O*-GlcNAc participates in regulating several aspects of transcription.

Synaptic proteins and neuronal communication

Consistent with the observation that OGT and OGA are highly active at synapses, proteomic studies have uncovered a number of synaptic proteins in the *O*-GlcNAc proteome^{19,44,49,50} (Fig. 2). Many of these proteins are enriched in the postsynaptic density, where they participate in the regulation of dendritic spine morphology and associate with the cytoskeleton. For instance, synaptopodin⁴⁴, synGAP¹⁹, and SH3 and multiple ankyrin repeat domains protein 2 (SHANK2)⁴⁹ are crucial for the normal formation of dendritic spine apparatuses^{51–53}, and synaptopodin and δ -catenin have important roles in learning and memory^{51,54}.

O-GlcNAc modifications are also highly abundant in presynaptic terminals. Several proteins involved in neurotransmitter release or synaptic vesicle endocytosis, such as bassoon⁴⁴, piccolo⁴⁹, synapsin⁴⁹ and clathrin assembly protein (AP180)⁵⁵, are *O*-GlcNAc glycosylated. The *O*-GlcNAc-modified collapsin response mediator protein 2 (CRMP2, also known as DPYSL2)¹⁹ has key roles in axon formation, elongation and branching⁵⁶. Moreover, many cytoskeletal proteins themselves are known to be glycosylated, including tau⁵⁷, the neurofilament proteins NF-H⁵⁸, NF-L⁴⁹ and NF-M⁴⁹, and the microtubule-associated proteins MAP1B⁴⁴ and MAP2B⁴⁴.

Additional functional studies are needed to define the mechanisms by which *O*-GlcNAc regulates these proteins. Nonetheless, its prevalence on proteins intricately involved in neurotransmitter release and cytoskeletal rearrangements underlying synaptic plasticity suggests roles for *O*-GlcNAc in regulating key neuronal functions. As described below, emerging evidence indicates that *O*-GlcNAc levels can be dynamically modulated in response to neuronal stimuli. Moreover, the potential interplay between *O*-GlcNAc and kinase pathways in neurons may provide a powerful means to control protein function and modulate neuronal communication processes.

Neurodegenerative disease

O-GlcNAc glycosylation has been implicated in several neurodegenerative diseases, such as Alzheimer's disease^{57,59,60} and amyotrophic lateral sclerosis (ALS)⁶¹. The genes encoding OGA and OGT map to chromosomal regions associated with late-onset Alzheimer's disease⁶² and dystonia-Parkinsonism syndrome⁶³, respectively. Moreover, *O*-GlcNAc levels are abnormally altered in the brains of individuals with Alzheimer's disease, although the magnitude and direction of the change seems to depend on the subcellular protein fraction^{59,60}.

In the pathology of Alzheimer's disease, the microtubule protein tau becomes hyperphosphorylated, which in turn favors its aggregation to form neurofibrillary tangles, which are hallmarks of the disease⁶⁴. Tau is extensively *O*-GlcNAc glycosylated in the adult rat brain, although the estimated 12 or more modification sites have yet to be mapped⁵⁷. Importantly, several studies suggest that *O*-GlcNAc glycosylation of tau negatively regulates its ability to be phosphorylated. For instance, inducing tau glycosylation with OGA inhibitors or by overexpression of OGT decreases tau phosphorylation at specific sites^{60,65}. Conversely, stimulation of hyperphosphorylated tau using the phosphatase inhibitor okadaic acid leads to hypoglycosylated tau in human neuroblastoma cells⁶⁶. Neuron-specific deletion of the OGT gene in mice induces hyperphosphorylated tau similar to that found in Alzheimer's disease¹⁷. As impaired glucose uptake and metabolism have been linked to Alzheimer's disease and seem to worsen as the disease progresses⁶⁷, one theory is that tau glycosylation becomes reduced in affected individuals, leading to hyperphosphorylated tau. Consistent with this view, mouse models of starvation that mimic this impaired glucose

metabolism show reduced tau glycosylation and a corresponding increase in tau phosphorylation at specific sites^{60,68}.

Abnormal *O*-GlcNAc glycosylation may also contribute to neurodegenerative diseases in more diverse ways. The amyloid precursor protein (APP), which forms the β -amyloid plaques characteristic of Alzheimer's disease, is both *O*-GlcNAc glycosylated and phosphorylated²⁰. In an animal model of ALS, the *O*-GlcNAc levels of neurofilament protein M are decreased at the same time as its phosphorylation levels are increased⁶¹. Finally, *O*-GlcNAc glycosylation has been demonstrated to inhibit the proteasome⁶⁹, thus providing a mechanism to couple ubiquitin-mediated protein degradation to the general metabolic state of the cell. Blocking the removal of *O*-GlcNAc from the proteasome leads to increased protein ubiquitination⁶⁹ and possibly neuronal apoptosis⁷⁰. Proteasomal dysfunction and ubiquitinated inclusion bodies are found in the diseased tissue of individuals with ALS, Parkinson's disease, Huntington's disease and Alzheimer's disease⁷¹. Thus, aberrations in glucose metabolism and the *O*-GlcNAc glycosylation of specific proteins have been associated with several neurodegenerative disorders. It will be important to determine the extent to which such changes are crucial to the development and progression of these diseases.

***O*-GlcNAc dynamics and cycling**

A unique feature of *O*-GlcNAc glycosylation is its ability to undergo dynamic cycling, in contrast to other, more static forms of protein glycosylation. Studies have shown that *O*-GlcNAc levels are altered by extracellular stimuli on a similar time scale to phosphorylation. For instance, a transient increase in glycosylation of the transcription factor nuclear factor activated T cells (NFAT) was observed within 5 min after T- or B-cell activation⁷².

O-GlcNAc levels are highly responsive to glucose concentrations and influx through the hexosamine biosynthesis pathway (HBP) in neurons and other cell types^{73,74}.

Approximately 2–5% of all cellular glucose is metabolized through the HBP pathway to generate UDP-GlcNAc⁷⁵. As OGT activity is exquisitely sensitive to UDP-GlcNAc concentrations⁷⁶, *O*-GlcNAc glycosylation may act as a sensor for the general metabolic state of the cell. Consistent with this idea, *O*-GlcNAc has been intricately linked to cell survival¹⁷ and is induced by many forms of cell stress⁷⁷.

In the brain, phosphorylation serves as a central mechanism for neuronal communication by regulating ion channels, neurotransmitter receptors, gene transcription and synaptic vesicle release^{78,79}. Protein kinases and phosphatases work together to coordinate different forms of synaptic plasticity, and they are necessary for the induction and maintenance of postsynaptic long-term potentiation and long-term depression⁸⁰. Thus, the potential interplay between *O*-GlcNAc glycosylation and phosphorylation has exciting implications for many neuronal functions. Early studies showed that activation of protein kinase C (PKC) or cAMP-dependent protein kinase (PKA) significantly decreased overall *O*-GlcNAc glycosylation in the cytoskeletal protein fraction of cultured cerebellar neurons²¹. Conversely, inhibition of PKC, PKA, cyclin-dependent protein kinases or S6 kinase increased overall *O*-GlcNAc levels in these fractions. A more complex relationship was observed with tyrosine kinases and phosphatases: inhibition of tyrosine phosphatases led to a decrease in overall *O*-GlcNAc levels, whereas inhibition of tyrosine kinases induced both increases and decreases in *O*-GlcNAc, depending on the protein fraction.

O-GlcNAc also seems to have important signaling functions that are independent of its relationship to phosphorylation. Recent quantitative proteomics studies have shown that *O*-GlcNAc glycosylation is dynamic and is induced by excitatory neuronal stimuli *in vivo*¹⁹. Dynamic changes in *O*-GlcNAc glycosylation of specific proteins were observed when rats

were administered kainic acid, which activates multiple excitatory signaling pathways involved in the stress response and synaptic plasticity. The increases in glycosylation reached a maximum after 6 hours and then returned to basal levels, demonstrating the reversible nature of *O*-GlcNAc in the brain. Interestingly, not all of the *O*-GlcNAc-modified proteins showed site-specific increases in glycosylation, suggesting that *O*-GlcNAc is subject to complex regulation within neurons.

Altogether, the emerging evidence suggests that *O*-GlcNAc represents a key regulatory modification in the brain. Not only is it present on many functionally important proteins, it seems to be reversible, differentially regulated and responsive to neuronal activity. Further studies are needed to elucidate the molecular mechanisms involved and how activation of specific signaling pathways leads to the regulation of OGT and OGA. Moreover, with the exception of the last example, changes in *O*-GlcNAc glycosylation have been monitored only on a global level, and the specific proteins undergoing dynamic changes in glycosylation remain largely unknown. As described below, new chemical approaches are being developed that should enable such questions to be addressed and provide new insights into the complex cellular dynamics of *O*-GlcNAc.

Chemical approaches to address the challenges of *O*-GlcNAc

Recent advances in our understanding of the cellular functions of *O*-GlcNAc have been accelerated by the development of chemical tools for studying the modification. Although *O*-GlcNAc glycosylation was discovered more than 20 years ago, its extent and functional significance are only beginning to be understood. A major challenge has been the difficulty of detecting and studying the modification *in vivo*. Like other post-translational modifications, *O*-GlcNAc is often dynamic, substoichiometric, targeted to specific subcellular compartments and prevalent on low-abundance regulatory proteins. The sugar is also enzymatically and chemically labile, being subject to reversal by cellular glycosidases and cleavage on a mass spectrometer. As with many protein kinases, the lack of a well-defined consensus sequence for OGT has precluded the determination of *in vivo* modification sites on the basis of the primary sequence. Here we highlight some chemical approaches designed to overcome these challenges and advance a fundamental understanding of *O*-GlcNAc.

Rapid, sensitive detection

Traditional methods for detecting *O*-GlcNAc glycosylation include the use of wheat germ agglutinin (WGA) lectin⁸¹, pan-specific *O*-GlcNAc antibodies^{73,77} or radiolabeling using β -1,4-galactosyltransferase (GalT)⁸², which transfers [³H]Gal from UDP-[³H]galactose to terminal GlcNAc groups. Although these approaches have greatly facilitated studies of the modification, many *O*-GlcNAc proteins still elude detection. For instance, tritium labeling suffers from low sensitivity, often necessitating exposure times of several days to months. *O*-GlcNAc antibodies and lectins have limited binding affinity and specificity, and therefore are best suited for highly glycosylated proteins with several modification sites.

Recently, chemical approaches have been developed to tag *O*-GlcNAc proteins with reporter groups such as biotin to enable more rapid, sensitive detection. Khidekel and co-workers designed an unnatural substrate for GalT containing a ketone moiety at the C2 position of UDP-galactose⁸³ (Fig. 3a). An engineered enzyme with a single Y289L mutation that enlarges the binding pocket⁸⁴ was used to transfer the ketogalactose sugar onto *O*-GlcNAc proteins of interest. Once transferred, the ketone functionality was reacted with an aminooxy biotin derivative and detected by chemiluminescence using streptavidin conjugated to horseradish peroxidase. This approach provides a significant improvement in sensitivity, enabling detection of proteins beyond the reach of traditional methods (Fig. 3b). The biotin

handle also facilitates isolation of the glycoproteins from cell or tissue extracts, thus circumventing the need to develop purification procedures for each protein of interest. As such, virtually any protein can be readily interrogated for the modification, and comparisons can be made across specific functional classes. For instance, Tai and co-workers have applied the approach to demonstrate that numerous transcriptional regulatory proteins are *O*-GlcNAc glycosylated *in vivo*, including transcription factors, transcriptional coactivators and corepressors⁸⁵. A variant of this method is now commercially available, in which a UDP azidogalactose substrate is used in conjunction with 'click' chemistry to transfer alkyne-containing reporter groups⁸⁶ (Fig. 3c).

A complementary strategy involves tagging *O*-GlcNAc-modified proteins through metabolic labeling of living cells with *N*-azido-acetylglucosamine (GlcNAz)⁸⁷. Vocadlo and co-workers showed that the azido sugar is processed by enzymes in the hexosamine salvage pathway and forms *O*-GlcNAz-modified proteins. The bioorthogonal azide moiety can then be derivatized with a FLAG peptide or a biotin tag using the Staudinger ligation. Treatment of Jurkat cells with peracetylated *N*-azidoacetylglucosamine led to labeling of the highly glycosylated nuclear pore protein p62, as detected by immuno-precipitation of p62 and western blotting. Although the labeling efficiency and sensitivity of this approach could not be evaluated and may depend on cell type, the ability to incorporate bioorthogonal groups selectively into *O*-GlcNAc proteins represents a powerful strategy for the detection of *O*-GlcNAc proteins in living cells.

Mapping *O*-GlcNAc glycosylation sites

Mapping the sites of *O*-GlcNAc glycosylation within proteins is essential for elucidating the functional roles of *O*-GlcNAc in specific biological contexts. Unfortunately, direct observation of the *O*-GlcNAc moiety by mass spectrometry during collision-induced dissociation (CID) is difficult, as the glycosidic linkage is labile and readily cleaved, providing little peptide fragmentation⁴⁴. Moreover, although OGT seems to favor sequences rich in proline, serine and threonine residues⁴⁴, there is no apparent consensus sequence that directs the action of OGT.

The development of chemical tools coupled to mass spectrometry has greatly facilitated the localization of *O*-GlcNAc to short peptide sequences within proteins, and this combination can be used to determine exact glycosylation sites. One approach, which relies on β -elimination followed by Michael addition with dithiothreitol (BEMAD), results in replacement of the labile GlcNAc moiety with a more stable sulfide adduct⁵⁰ (Fig. 4). As this adduct is not cleaved upon CID, sites of glycosylation can be more readily determined. However, selectivity controls must be carried out to distinguish *O*-GlcNAc from *O*-phosphate and other *O*-linked carbohydrates. Extension of BEMAD to proteomic studies for the high-throughput mapping of *O*-GlcNAc sites is an important future goal.

A second approach capitalizes on the ability to selectively biotinylate *O*-GlcNAc proteins using ketone- or azide-containing UDP-galactose sugars as described above (Fig. 3). In addition to isolating intact proteins, the biotin handle can be used to enrich *O*-GlcNAc peptides following proteolytic digestion⁴⁴. This enrichment step is essential for mass spectrometric detection because the *O*-GlcNAc-modified species represents only a small fraction of the total peptides. Unlike BEMAD, the approach enables direct detection of the *O*-GlcNAc moiety by mass spectrometry, with the GlcNAc-ketogalactose-biotin tag providing a unique fragmentation pattern for unambiguous identification of *O*-GlcNAc peptides⁴⁴. Notably, the strategy has been applied to both individual proteins and complex mixtures to localize the modification to short sequences in more than 50 different proteins. However, mapping exact glycosylation sites remains challenging in most cases owing to the lability of the *O*-glycosidic linkage. As a potential solution to this problem, Khidekel and

co-workers demonstrated that this ketogalactose-biotin tagging approach could be combined with BEMAD to identify specific glycosylation sites on the HIV-1 Rev binding protein⁴⁴. Similarly, Wang and co-workers recently used azidogalactose-biotin tagging in conjunction with BEMAD to map glycosylation sites on vimentin⁸⁸.

Newer mass spectrometry approaches such as electron transfer dissociation (ETD) and electron capture dissociation (ECD) promise to greatly accelerate our ability to identify *O*-GlcNAc modification sites. ETD and ECD produce sequence-specific fragmentation of peptides without the loss of labile post-translational modifications such as phosphorylation and glycosylation⁸⁹. As such, these approaches are ideal for mapping *O*-GlcNAc glycosylation sites. Vosseller and co-workers demonstrated that ECD can be used to identify modification sites on several neuronal proteins following enrichment of the glycopeptides by lectin weak-affinity chromatography⁴⁹. More recently, Khidekel and co-workers applied the ketogalactose-biotin tagging approach in conjunction with ETD to map glycosylation sites on proteins from rat brain lysates¹⁹. In contrast to ECD, which requires the use of Fourier transform instrumentation, ETD can be carried out directly in appropriately modified ion trap mass spectrometers. Thus, the speed, sensitivity and accessibility of ETD to most laboratories make it an ideal emerging technology. With further methodological refinements and advances in database search algorithms for fragment ions, we anticipate that ETD and ECD will become increasingly powerful tools for the study of *O*-GlcNAc glycosylation.

Proteome-wide analyses

As described earlier, the analysis of *O*-GlcNAc on a proteome level has begun to reveal exciting functional roles for *O*-GlcNAc in the brain. Chemical strategies to tag, enrich and detect *O*-GlcNAc peptides and proteins have been instrumental in this regard, enabling the first proteome-wide studies of *O*-GlcNAc. Specifically, the ketogalactose-biotin tagging approach (Fig. 3) has been applied in combination with high-throughput LC-MS/MS analysis to identify more than 45 *O*-GlcNAc-glycosylated proteins from the mammalian brain^{19,44}. Direct detection of the modified species was observed in each case, which allowed mapping of the glycosylation sites to short peptide sequences. Notably, many of the proteins identified participate in the regulation of gene expression (for example, CCR4–NOT, SOX2, SRC1, HCF and TLE4), neuronal signaling (WNK1, bassoon, PDZ-GEF) and synaptic plasticity (synGAP, synaptopodin), suggesting that *O*-GlcNAc may contribute to neuronal communication processes. In another approach, Nandi and co-workers metabolically labeled HeLa cells with *N*-(2-azido-acetyl) glucosamine⁹⁰. Tryptic digestion of the captured proteins led to the identification of 199 putative *O*-GlcNAc-modified proteins. As the presence of the GlcNAc moiety was inferred rather than detected directly, independent confirmation of the modification by immunoprecipitation was required and demonstrated for 23 of the proteins.

Recently, biochemical tools such as antibodies and lectins have been exploited for proteomic analyses of *O*-GlcNAc. Vosseller and co-workers used a uniquely packed, 39-foot lectin affinity column to enrich *O*-GlcNAc peptides and identified 18 proteins from the postsynaptic density fraction of murine brain tissue⁴⁹. Antibody affinity chromatography using a general *O*-GlcNAc antibody identified 45 putative *O*-GlcNAc proteins from COS7 cells⁸⁸. The challenge with both approaches is that the weak binding affinity of antibodies and lectins necessitates gentle washing conditions and can lead to false positives, such as interacting proteins or nonspecific binding proteins. In many cases, further confirmation of the presence of the modification can be provided by evaluating individually immunoprecipitated proteins or by directly detecting *O*-GlcNAc-modified peptides by mass spectrometry analysis.

Together, proteome-wide studies have revealed that *O*-GlcNAc is a ubiquitous and abundant modification found on proteins with considerable functional significance and breadth. In less than 5 years, the number of known *O*-GlcNAc proteins has expanded from tens to hundreds, with many more proteins yet to be discovered.

Small-molecule inhibitors of OGT and OGA

Historically, genetic manipulation of OGT and OGA activity *in vivo* has proven difficult. Whole-animal and conditional deletions of the OGT gene have revealed that OGT is essential for cell survival and mouse embryogenesis^{17,91}. Modulation of OGT using small interfering RNAs is complicated by the long half-life of the protein and often produces only partial knockdown of OGT⁹². Although deletion of OGA in *Caenorhabditis elegans* leads to metabolic changes and increased dauer formation⁹³, no mammalian knockout of OGA has yet been reported. These features have challenged efforts to study *O*-GlcNAc glycosylation and have limited the use of conventional genetic tools to elucidate its role in cellular processes.

A complementary approach involves the generation of pharmacological agents to inhibit OGT and OGA. A well-established inhibitor of OGT, alloxan, shows multiple nonspecific effects, such as inhibition of OGA⁹⁴, glucokinase inhibition⁹⁵ and formation of superoxide radicals⁹⁶. By screening a 64,416-member library of compounds using a novel fluorescence-based assay, Gross and co-workers identified several promising new compounds that inhibit OGT activity *in vitro*⁹⁷ (Fig. 5a, compounds 1–3). These compounds were selective in inhibiting OGT but not another related enzyme, MurG, which also uses UDP-GlcNAc as a substrate. Recently, a benzoxazolinone compound (Fig. 5a, compound 1) was shown to inhibit OGT activity in oocytes, where it prevents meiotic progression⁹⁸. In the future, these numerous, chemically distinct OGT inhibitors might be used in parallel to distinguish the potential nonspecific effects of individual inhibitors *in vivo*.

Many of the early OGA inhibitors such as PUGNAc (*O*-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-*N*-phenylcarbamate) exhibit nonspecific activity toward β -hexosaminidase⁹⁹ and only partially inhibit the short isoform of OGA¹⁰⁰. Recently, several laboratories have designed more selective OGA inhibitors that either are structural variants of early hexosaminidase inhibitors and/or have been rationally designed using information about the enzyme active site. For instance, Macauley *et al.* and Knapp *et al.* functionalized the nonspecific hexosaminidase inhibitor GlcNAc-thiazoline with longer alkyl chains or fluoro or azido groups to generate new OGA inhibitors that show greater than 3,000-fold selective inhibition of OGA over β -hexosaminidase^{101,102} (Fig. 5b, compounds 4–6). In other studies, extending the *N*-acyl group of PUGNAc led to the creation of new inhibitors with greater than ten-fold selectivity for OGA over β -hexosaminidase^{99,103}. A drawback of these compounds is that they inhibit OGA more weakly than PUGNAc. In response to this problem, Dorfmeuller and co-workers designed a nagstatin derivative based on the crystal structure of NagJ, a bacterial homolog of human OGA¹⁰⁴ (Fig. 5b, compound 7). The isobutanamido group at the N8 position (tetrahydroimidazopyridine numbering) provides improved selectivity by fitting into a pocket that is larger than the corresponding pockets in other hexosaminidases, whereas the phenethyl group at the C2 position offers stronger inhibition ($K_i = 4.6 \pm 0.1$ pM) for the bacterial homolog of OGA by interacting with a solvent-exposed tryptophan residue. Nonetheless, a related nagstatin derivative still showed weaker inhibition toward human OGA than PUGNAc¹⁰⁵. More recently, Kim and co-workers designed a compound that strongly inhibits the short isoform of OGA¹⁰⁰ (Fig. 5, compound 8), an isoform that is only partially inhibited by 1 mM PUGNAc. However, selectivity may be an issue with this compound, as thiosulfonate moieties have been shown to react with exposed cysteine residues of proteins¹⁰⁶. Notably, compounds 4 and 7 have been tested in cell culture and were shown to increase overall cellular *O*-GlcNAc levels.

The discovery of potent, selective inhibitors of OGT and OGA provides powerful tools for perturbing *O*-GlcNAc glycosylation in cells and *in vivo*. Application of these inhibitors in specific contexts should reveal new insights into the functional roles of *O*-GlcNAc and cellular mechanisms for the regulation of OGT and OGA.

Monitoring *O*-GlcNAc dynamics

The dynamic nature of *O*-GlcNAc is a unique characteristic that distinguishes it from other forms of glycosylation. As described earlier, this feature has important implications for the regulation of protein structure and function and the interplay with other post-translational modifications. An exciting challenge in the future will be to understand the cellular dynamics of the modification, as well as the signaling pathways and mechanisms by which *O*-GlcNAc is regulated on specific proteins. Toward this end, several groups have developed chemical approaches to monitor changes in *O*-GlcNAc glycosylation levels in response to cellular stimuli.

Carrillo and co-workers designed a fluorescence resonance energy transfer (FRET)-based sensor for the detection of *O*-GlcNAc dynamics in living cells¹⁰⁷. Their sensor consisted of two fluorophores (enhanced cyan and yellow fluorescent protein) separated by a known peptide substrate for OGT and an *O*-GlcNAc lectin (GafD). Upon *O*-GlcNAc glycosylation, the lectin was expected to bind the glycosylated peptide substrate and bring the two fluorophores in close proximity, producing a stronger FRET signal (Fig. 6a). As anticipated, an increase in FRET (7–30%) was observed upon stimulation of transfected HeLa cells with PUGNAc and glucosamine. In the future, it will be interesting to examine changes in OGT activity in response to a variety of cellular stimuli.

In addition to monitoring OGT activity, identifying the intracellular signaling pathways and dynamics of *O*-GlcNAc glycosylation on specific protein substrates represents an important, challenging goal. General *O*-GlcNAc antibodies (CTD110.6 and RL-2) have been extremely valuable for measuring global changes in glycosylation in response to cellular stimuli^{73, 77}. However, a limitation of these antibodies is that they detect only a small subset of the *O*-GlcNAc-modified proteins^{19, 83}. Moreover, it remains difficult to identify the specific proteins that undergo changes in glycosylation. In response to these challenges, Khidekel and co-workers have developed a method to probe the dynamics of *O*-GlcNAc glycosylation *in vivo* using quantitative proteomics¹⁹ (Fig. 6b). The quantitative isotopic and chemoenzymatic tagging (QUIC-Tag) approach involves chemoenzymatically labeling proteins from two different cell states (for example, stimulated versus unstimulated) with a ketogalactose- biotin reporter group as described above. Following proteolytic digestion, the peptides are isotopically labeled using reductive amination chemistry to distinguish the two populations and subsequently combined. The biotinylated *O*-GlcNAc peptides are enriched using avidin chromatography, then quantified and sequenced by mass spectrometry. Using this approach, proteins undergoing dynamic changes in glycosylation can be identified, and glycosylation changes at specific sites within proteins can be monitored in response to cellular stimulation. Khidekel and co-workers found that *O*-GlcNAc glycosylation is induced on certain proteins upon excitatory stimulation of the rodent brain *in vivo*. Whereas some sites of glycosylation underwent robust changes in occupancy, other sites remained unchanged, suggesting that *O*-GlcNAc is subject to complex regulation within neurons. The reversible and highly regulated nature of *O*-GlcNAc, along with the observation that excitatory stimulation induces glycosylation, supports the idea that *O*-GlcNAc is an important, regulatory modification in the brain.

More recently, Wang and co-workers used immunoaffinity chromatography in conjunction with SILAC (stable isotope labeling with amino acids in cell culture), a well-established method for quantitative proteomics¹⁰⁸, to study the dynamic interplay between *O*-GlcNAc

and phosphorylation by glycogen synthase kinase-3 (GSK3)⁸⁸. Heavy and light isotope-labeled cells were treated with lithium chloride to inhibit GSK3, and *O*-GlcNAc proteins of interest were isolated by affinity chromatography using a general *O*-GlcNAc antibody. Forty-five putative *O*GlcNAc– glycosylated proteins were identified by mass spectrometry, ten of which showed enrichment after lithium chloride treatment, suggesting that these proteins underwent increases in *O*-GlcNAc glycosylation. In four of the cases, the glycosylation increases that were observed indirectly by mass spectrometry were confirmed by immunoprecipitation. Interestingly, other proteins showed either no change or decreased glycosylation, suggesting that a complex interplay is likely to exist between phosphorylation and *O*-GlcNAc glycosylation within signaling networks.

With these new tools, in-depth studies of the dynamics of *O*-GlcNAc within cells are now within reach. Understanding the molecular mechanisms by which this dynamic signaling comes about and regulates specific proteins is a future challenge that promises to propel the field in exciting new directions.

Conclusion and future challenges

Over the past decade, a surge of discoveries in *O*-GlcNAc glycosylation has revealed new roles for this modification in the nervous system. *O*-GlcNAc is abundant in the brain and present on many diverse proteins involved in transcription, neuronal signaling and synaptic plasticity. Indeed, recent studies have begun to uncover the functional roles of *O*-GlcNAc, its complex dynamics in the brain and the interplay between *O*-GlcNAc and phosphorylation. Many of these discoveries have been accelerated by the development of new chemical tools, such as those for detecting the *O*-GlcNAc modification in cells and for inhibiting OGT and OGA. Combined with advances in mass spectrometry, these new technologies have provided an unprecedented opportunity to define the *O*-GlcNAc proteome, manipulate *O*-GlcNAc enzymes and explore the dynamics of this modification *in vivo*.

Although the pace and scope of understanding *O*-GlcNAc has expanded considerably, much remains to be discovered. Owing to the challenge of studying the modification, evidence linking *O*-GlcNAc to specific biological functions has often been indirect or correlative. This is particularly true in the brain, where the complexity of the nervous system and its unique technical challenges (for example, postmitotic cells, the complex organization of the brain, the presence of multiple cell types and the blood-brain barrier) render *O*-GlcNAc more difficult to investigate. Nonetheless, in-depth functional studies on proteins will be essential in the future to determine the roles of *O*-GlcNAc in neuronal-specific contexts.

The development of new chemical tools to produce homogeneously glycosylated proteins will represent an important step toward this goal. Unlike phosphorylation, *O*-GlcNAc glycosylation cannot be readily mimicked by any naturally occurring amino acid. At best, alanine mutagenesis of specific glycosylation sites within proteins can be used to effect changes in function. Chemical methods such as nonsense suppression¹⁰⁹ and native chemical ligation¹¹⁰ may allow for the construction of *O*-GlcNAc–glycosylated proteins *in vitro* and in cells. In the future, these methods may provide new insights into whether and how *O*-GlcNAc glycosylation affects protein structure, modulates protein-protein interactions and influences other post-translational modifications.

One of the central challenges of neuroscience is to understand the unique molecular and cellular heterogeneity of the brain as it relates to systems-level phenomena such as learning and memory. Sensitive methods to detect the modification on small subpopulations of cells or proteins will be required to dissect the role of *O*-GlcNAc in fear, addiction and other

complex learning and memory models. Despite significant progress, faster, higher-throughput methods are still needed to identify *O*-GlcNAc proteins and study *O*-GlcNAc dynamics *in vivo*. For instance, the ability to directly monitor the glycosylation status of specific proteins using chemical tagging approaches or site-specific *O*-GlcNAc antibodies will be essential. To facilitate the production of *O*-GlcNAc antibodies, facile synthetic routes to access *O*-GlcNAc–modified peptides are needed. Moreover, the continued development of methods to precisely map glycosylation sites, particularly on small quantities of material and on selected proteins of interest, will be crucial for any functional studies.

New sensitive and selective OGT and OGA inhibitors will be important tools for finely dissecting the role of each enzyme in neuronal function and dysfunction. Given the diversity of OGT and OGA substrates, and the lethality of deleting the OGT gene in mice, creative new genetic or chemical approaches are needed to more selectively target functional subsets of OGT and OGA by interfering, for instance, with the enzymes in certain subcellular compartments.

From the time of its discovery, the appeal of *O*-GlcNAc has been both the intrigue of understanding its unique biology and the great technical challenges associated with its study. Over the past 5 years, we have seen a surge of new chemistry designed to meet these obstacles. Strengthened by an arsenal of chemical tools, the future of *O*-GlcNAc is primed for new and exciting discoveries.

Acknowledgments

We thank C.J. Rogers and H.E. Murrey for critical reading of the manuscript. This work was supported in part by grants from the US National Institutes of Health (RO1 GM084724 and F31 NS056525-02 to J.E.R.) and the US National Science Foundation (CHE-0239861).

References

1. Torres CR, Hart GW. Topography and polypeptide distribution of terminal *N*-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for *O*-linked GlcNAc. *J Biol Chem*. 1984; 259:3308–3317. [PubMed: 6421821]
2. Love DC, Hanover JA. The hexosamine signaling pathway: deciphering the ‘*O*-GlcNAc code’. *Sci STKE*. 2005; 2005:re13. [PubMed: 16317114]
3. Roquemore EP, Chevrier MR, Cotter RJ, Hart GW. Dynamic *O*-GlcNAcylation of the small heat shock protein α B-crystallin. *Biochemistry*. 1996; 35:3578–3586. [PubMed: 8639509]
4. Comer FI, Hart GW. *O*-GlcNAc and the control of gene expression. *Biochim Biophys Acta*. 1999; 1473:161–171. [PubMed: 10580136]
5. Zachara NE, Hart GW. *O*-GlcNAc a sensor of cellular state: the role of nucleo-cytoplasmic glycosylation in modulating cellular function in response to nutrition and stress. *Biochim Biophys Acta*. 2004; 1673:13–28. [PubMed: 15238246]
6. Fulop N, Marchase RB, Chatham JC. Role of protein *O*-linked *N*-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system. *Cardiovasc Res*. 2007; 73:288–297. [PubMed: 16970929]
7. Wells L, Hart GW. *O*-GlcNAc turns twenty: functional implications for posttranslational modification of nuclear and cytosolic proteins with a sugar. *FEBS Lett*. 2003; 546:154–158. [PubMed: 12829252]
8. Wells L, Whelan SA, Hart GW. *O*-GlcNAc: a regulatory post-translational modification. *Biochem Biophys Res Commun*. 2003; 302:435–441. [PubMed: 12615051]
9. Slawson C, Hart GW. Dynamic interplay between *O*-GlcNAc and *O*-phosphate: the sweet side of protein regulation. *Curr Opin Struct Biol*. 2003; 13:631–636. [PubMed: 14568619]

10. Wells L, Vosseller K, Hart GW. A role for *N*-acetylglucosamine as a nutrient sensor and mediator of insulin resistance. *Cell Mol Life Sci*. 2003; 60:222–228. [PubMed: 12678487]
11. Lefebvre T, et al. Does *O*-GlcNAc play a role in neurodegenerative diseases? *Expert Rev Proteomics*. 2005; 2:265–275. [PubMed: 15892570]
12. Lefebvre T, Caillet-Boudin ML, Buee L, Delacourte A, Michalski JC. *O*-GlcNAc glycosylation and neurological disorders. *Adv Exp Med Biol*. 2003; 535:189–202. [PubMed: 14714896]
13. Kreppel LK, Blomberg MA, Hart GW. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique *O*-GlcNAc transferase with multiple tetratricopeptide repeats. *J Biol Chem*. 1997; 272:9308–9315. [PubMed: 9083067]
14. Gao Y, Wells L, Comer FI, Parker GJ, Hart GW. Dynamic *O*-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic β -*N*-acetylglucosaminidase from human brain. *J Biol Chem*. 2001; 276:9838–9845. [PubMed: 11148210]
15. Akimoto Y, et al. Localization of the *O*-GlcNAc transferase and *O*-GlcNAc-modified proteins in rat cerebellar cortex. *Brain Res*. 2003; 966:194–205. [PubMed: 12618343]
16. Cole RN, Hart GW. Cytosolic *O*-glycosylation is abundant in nerve terminals. *J Neurochem*. 2001; 79:1080–1089. [PubMed: 11739622]
17. O'Donnell N, Zachara NE, Hart GW, Marth JD. *Ogt*-dependent X-chromosome-linked protein glycosylation is a requisite modification in somatic cell function and embryo viability. *Mol Cell Biol*. 2004; 24:1680–1690. [PubMed: 14749383]
18. Lamarre-Vincent N, Hsieh-Wilson LC. Dynamic glycosylation of the transcription factor CREB: a potential role in gene regulation. *J Am Chem Soc*. 2003; 125:6612–6613. [PubMed: 12769553]
19. Khidekel N, et al. Probing the dynamics of *O*-GlcNAc glycosylation in the brain using quantitative proteomics. *Nat Chem Biol*. 2007; 3:339–348. [PubMed: 17496889]
20. Griffith LS, Mathes M, Schmitz B. β -Amyloid precursor protein is modified with *O*-linked *N*-acetylglucosamine. *J Neurosci Res*. 1995; 41:270–278. [PubMed: 7650762]
21. Griffith LS, Schmitz B. *O*-linked *N*-acetylglucosamine levels in cerebellar neurons respond reciprocally to perturbations of phosphorylation. *Eur J Biochem*. 1999; 262:824–831. [PubMed: 10411645]
22. Lazarus BD, Love DC, Hanover JA. Recombinant *O*-GlcNAc transferase isoforms: identification of *O*-GlcNAcase, yes tyrosine kinase, and tau as isoform-specific substrates. *Glycobiology*. 2006; 16:415–421. [PubMed: 16434389]
23. Kreppel LK, Hart GW. Regulation of a cytosolic and nuclear *O*-GlcNAc transferase. Role of the tetratricopeptide repeats. *J Biol Chem*. 1999; 274:32015–32022. [PubMed: 10542233]
24. Jinek M, et al. The superhelical TPR-repeat domain of *O*-linked GlcNAc transferase exhibits structural similarities to importin α . *Nat Struct Mol Biol*. 2004; 11:1001–1007. [PubMed: 15361863]
25. Iyer SP, Akimoto Y, Hart GW. Identification and cloning of a novel family of coiled-coil domain proteins that interact with *O*-GlcNAc transferase. *J Biol Chem*. 2003; 278:5399–5409. [PubMed: 12435728]
26. Brickley K, Smith MJ, Beck M, Stephenson FA. GRIF-1 and OIP106, members of a novel gene family of coiled-coil domain proteins: association *in vivo* and *in vitro* with kinesin. *J Biol Chem*. 2005; 280:14723–14732. [PubMed: 15644324]
27. Stowers RS, Megeath LJ, Gorska-Andrzejak J, Meinertzhagen IA, Schwarz TL. Axonal transport of mitochondria to synapses depends on Milton, a novel *Drosophila* protein. *Neuron*. 2002; 36:1063–1077. [PubMed: 12495622]
28. Yang X, Zhang F, Kudlow JE. Recruitment of *O*-GlcNAc transferase to promoters by corepressor mSin3A: coupling protein *O*-GlcNAcylation to transcriptional repression. *Cell*. 2002; 110:69–80. [PubMed: 12150998]
29. Wells L, Kreppel LK, Comer FI, Wadzinski BE, Hart GW. *O*-GlcNAc transferase is in a functional complex with protein phosphatase 1 catalytic subunits. *J Biol Chem*. 2004; 279:38466–38470. [PubMed: 15247246]
30. Wells L, et al. Dynamic *O*-glycosylation of nuclear and cytosolic proteins: further characterization of the nucleocytoplasmic β -*N*-acetylglucosaminidase, *O*-GlcNAcase. *J Biol Chem*. 2002; 277:1755–1761. [PubMed: 11788610]

31. Toleman C, Paterson AJ, Whisenhunt TR, Kudlow JE. Characterization of the histone acetyltransferase (HAT) domain of a bifunctional protein with activable *O*-GlcNAcase and HAT activities. *J Biol Chem*. 2004; 279:53665–53673. [PubMed: 15485860]
32. Comtesse N, Maldener E, Meese E. Identification of a nuclear variant of MGEA5, a cytoplasmic hyaluronidase and a β -*N*-acetylglucosaminidase. *Biochem Biophys Res Commun*. 2001; 283:634–640. [PubMed: 11341771]
33. Kelly WG, Hart GW. Glycosylation of chromosomal proteins: localization of *O*-linked *N*-acetylglucosamine in *Drosophila* chromatin. *Cell*. 1989; 57:243–251. [PubMed: 2495182]
34. Jackson SP, Tjian R. *O*-glycosylation of eukaryotic transcription factors: implications for mechanisms of transcriptional regulation. *Cell*. 1988; 55:125–133. [PubMed: 3139301]
35. Zachara NE, Hart GW. Cell signaling, the essential role of *O*-GlcNAc! *Biochim Biophys Acta*. 2006; 1761:599–617. [PubMed: 16781888]
36. Yang X, et al. *O*-linkage of *N*-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. *Proc Natl Acad Sci USA*. 2001; 98:6611–6616. [PubMed: 11371615]
37. Roos MD, Su K, Baker JR, Kudlow JE. *O* glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions. *Mol Cell Biol*. 1997; 17:6472–6480. [PubMed: 9343410]
38. Gewinner C, et al. The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. *J Biol Chem*. 2004; 279:3563–3572. [PubMed: 14597631]
39. Yang WH, et al. Modification of p53 with *O*-linked *N*-acetylglucosamine regulates p53 activity and stability. *Nat Cell Biol*. 2006; 8:1074–1083. [PubMed: 16964247]
40. Carlezon WA Jr, Duman RS, Nestler EJ. The many faces of CREB. *Trends Neurosci*. 2005; 28:436–445. [PubMed: 15982754]
41. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. *Nat Rev Mol Cell Biol*. 2001; 2:599–609. [PubMed: 11483993]
42. Levkovitz Y, Baraban JM. A dominant negative inhibitor of the Egr family of transcription regulatory factors suppresses cerebellar granule cell apoptosis by blocking c-Jun activation. *J Neurosci*. 2001; 21:5893–5901. [PubMed: 11487612]
43. Jones MW, et al. A requirement for the immediate early gene *Zif268* in the expression of late LTP and long-term memories. *Nat Neurosci*. 2001; 4:289–296. [PubMed: 11224546]
44. Khidekel N, Ficarro SB, Peters EC, Hsieh-Wilson LC. Exploring the *O*-GlcNAc proteome: direct identification of *O*-GlcNAc-modified proteins from the brain. *Proc Natl Acad Sci USA*. 2004; 101:13132–13137. [PubMed: 15340146]
45. Wilson M, Koopman P. Matching SOX: partner proteins and co-factors of the SOX family of transcriptional regulators. *Curr Opin Genet Dev*. 2002; 12:441–446. [PubMed: 12100890]
46. Rodda DJ, et al. Transcriptional regulation of nanog by OCT4 and SOX2. *J Biol Chem*. 2005; 280:24731–24737. [PubMed: 15860457]
47. Komitova M, Eriksson PS. Sox-2 is expressed by neural progenitors and astroglia in the adult rat brain. *Neurosci Lett*. 2004; 369:24–27. [PubMed: 15380301]
48. Collart MA. Global control of gene expression in yeast by the Ccr4–Not complex. *Gene*. 2003; 313:1–16. [PubMed: 12957374]
49. Vosseller K, et al. *O*-linked *N*-acetylglucosamine proteomics of postsynaptic density preparations using lectin weak affinity chromatography and mass spectrometry. *Mol Cell Proteomics*. 2006; 5:923–934. [PubMed: 16452088]
50. Wells L, et al. Mapping sites of *O*-GlcNAc modification using affinity tags for serine and threonine post-translational modifications. *Mol Cell Proteomics*. 2002; 1:791–804. [PubMed: 12438562]
51. Deller T, et al. Synaptopodin-deficient mice lack a spine apparatus and show deficits in synaptic plasticity. *Proc Natl Acad Sci USA*. 2003; 100:10494–10499. [PubMed: 12928494]
52. Vazquez LE, Chen HJ, Sokolova I, Knuesel I, Kennedy MB. SynGAP regulates spine formation. *J Neurosci*. 2004; 24:8862–8872. [PubMed: 15470153]
53. Sala C, et al. Regulation of dendritic spine morphology and synaptic function by Shank and Homer. *Neuron*. 2001; 31:115–130. [PubMed: 11498055]

54. Israely I, et al. Deletion of the neuron-specific protein δ -catenin leads to severe cognitive and synaptic dysfunction. *Curr Biol*. 2004; 14:1657–1663. [PubMed: 15380068]
55. Murphy JE, Hanover JA, Froehlich M, DuBois G, Keen JH. Clathrin assembly protein AP-3 is phosphorylated and glycosylated on the 50-kDa structural domain. *J Biol Chem*. 1994; 269:21346–21352. [PubMed: 8063760]
56. Yoshimura T, et al. GSK-3 β regulates phosphorylation of CRMP-2 and neuronal polarity. *Cell*. 2005; 120:137–149. [PubMed: 15652488]
57. Arnold CS, et al. The microtubule-associated protein tau is extensively modified with *O*-linked *N*-acetylglucosamine. *J Biol Chem*. 1996; 271:28741–28744. [PubMed: 8910513]
58. Dong DL, Xu ZS, Hart GW, Cleveland DW. Cytoplasmic *O*-GlcNAc modification of the head domain and the KSP repeat motif of the neurofilament protein neurofilament-H. *J Biol Chem*. 1996; 271:20845–20852. [PubMed: 8702840]
59. Griffith LS, Schmitz B. *O*-linked *N*-acetylglucosamine is upregulated in Alzheimer brains. *Biochem Biophys Res Commun*. 1995; 213:424–431. [PubMed: 7646495]
60. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX. *O*-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. *Proc Natl Acad Sci USA*. 2004; 101:10804–10809. [PubMed: 15249677]
61. Ludemann N, et al. *O*-glycosylation of the tail domain of neurofilament protein M in human neurons and in spinal cord tissue of a rat model of amyotrophic lateral sclerosis (ALS). *J Biol Chem*. 2005; 280:31648–31658. [PubMed: 16006557]
62. Van Tine BA, Patterson AJ, Kudlow JE. Assignment of *N*-acetyl-D-glucosaminidase (Mgea5) to rat chromosome 1q5 by tyramide fluorescence in situ hybridization (T-FISH): synteny between rat, mouse and human with insulin degradation enzyme (IDE). *Cytogenet Genome Res*. 2003; 103:202B.
63. Nolte D, Muller U. Human *O*-GlcNAc transferase (OGT): genomic structure, analysis of splice variants, fine mapping in Xq13.1. *Mamm Genome*. 2002; 13:62–64. [PubMed: 11773972]
64. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. *Nat Rev Neurosci*. 2007; 8:663–672. [PubMed: 17684513]
65. Robertson LA, Moya KL, Breen KC. The potential role of tau protein *O*-glycosylation in Alzheimer's disease. *J Alzheimers Dis*. 2004; 6:489–495. [PubMed: 15505370]
66. Lefebvre T, et al. Evidence of a balance between phosphorylation and *O*-GlcNAc glycosylation of Tau proteins—a role in nuclear localization. *Biochim Biophys Acta*. 2003; 1619:167–176. [PubMed: 12527113]
67. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. *Am J Psychiatry*. 2002; 159:738–745. [PubMed: 11986126]
68. Li X, Lu F, Wang JZ, Gong CX. Concurrent alterations of *O*-GlcNAcylation and phosphorylation of tau in mouse brains during fasting. *Eur J Neurosci*. 2006; 23:2078–2086. [PubMed: 16630055]
69. Zhang F, et al. *O*-GlcNAc modification is an endogenous inhibitor of the proteasome. *Cell*. 2003; 115:715–725. [PubMed: 14675536]
70. Liu K, et al. Accumulation of protein *O*-GlcNAc modification inhibits proteasomes in the brain and coincides with neuronal apoptosis in brain areas with high *O*-GlcNAc metabolism. *J Neurochem*. 2004; 89:1044–1055. [PubMed: 15140202]
71. Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. *Neuron*. 2003; 40:427–446. [PubMed: 14556719]
72. Golks A, Tran TT, Goetschy JF, Guerini D. Requirement for *O*-linked *N*-acetylglucosaminyltransferase in lymphocytes activation. *EMBO J*. 2007; 26:4368–4379. [PubMed: 17882263]
73. Liu K, Paterson AJ, Chin E, Kudlow JE. Glucose stimulates protein modification by *O*-linked GlcNAc in pancreatic β cells: linkage of *O*-linked GlcNAc to β cell death. *Proc Natl Acad Sci USA*. 2000; 97:2820–2825. [PubMed: 10717000]
74. Rex-Mathes M, et al. *O*-GlcNAc expression in developing and ageing mouse brain. *Biochimie*. 2001; 83:583–590. [PubMed: 11522386]

75. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. *J Biol Chem*. 1991; 266:4706–4712. [PubMed: 2002019]
76. Haltiwanger RS, Blomberg MA, Hart GW. Glycosylation of nuclear and cytoplasmic proteins. Purification and characterization of a uridine diphospho-*N*-acetylglucosamine: polypeptide β -*N*-acetylglucosaminyltransferase. *J Biol Chem*. 1992; 267:9005–9013. [PubMed: 1533623]
77. Zachara NE, et al. Dynamic *O*-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells. *J Biol Chem*. 2004; 279:30133–30142. [PubMed: 15138254]
78. Greengard P, Valtorta F, Czernik AJ, Benfenati F. Synaptic vesicle phosphoproteins and regulation of synaptic function. *Science*. 1993; 259:780–785. [PubMed: 8430330]
79. Soderling TR. CaM-kinases: modulators of synaptic plasticity. *Curr Opin Neurobiol*. 2000; 10:375–380. [PubMed: 10851169]
80. Colbran RJ. Protein phosphatases and calcium/calmodulin-dependent protein kinase II-dependent synaptic plasticity. *J Neurosci*. 2004; 24:8404–8409. [PubMed: 15456812]
81. Cieniewski-Bernard C, et al. Identification of *O*-linked *N*-acetylglucosamine proteins in rat skeletal muscle using two-dimensional gel electrophoresis and mass spectrometry. *Mol Cell Proteomics*. 2004; 3:577–585. [PubMed: 14985449]
82. Roquemore EP, Chou TY, Hart GW. Detection of *O*-linked *N*-acetylglucosamine (*O*-GlcNAc) on cytoplasmic and nuclear proteins. *Methods Enzymol*. 1994; 230:443–460. [PubMed: 8139512]
83. Khidekel N, et al. A chemoenzymatic approach toward the rapid and sensitive detection of *O*-GlcNAc posttranslational modifications. *J Am Chem Soc*. 2003; 125:16162–16163. [PubMed: 14692737]
84. Ramakrishnan B, Qasba PK. Structure-based design of β 1,4-galactosyltransferase I (β 4Gal-T1) with equally efficient *N*-acetylgalactosaminyltransferase activity: point mutation broadens β 4Gal-T1 donor specificity. *J Biol Chem*. 2002; 277:20833–20839. [PubMed: 11916963]
85. Tai HC, Khidekel N, Ficarro SB, Peters EC, Hsieh-Wilson LC. Parallel identification of *O*-GlcNAc-modified proteins from cell lysates. *J Am Chem Soc*. 2004; 126:10500–10501. [PubMed: 15327282]
86. Hsieh-Wilson, LC.; Khidekel, N.; Arndt, SE.; Tai, H-C. Method and compositions for the detection of protein glycosylation. US patent application. 20050130235. 2005.
87. Vocadlo DJ, Hang HC, Kim EJ, Hanover JA, Bertozzi CR. A chemical approach for identifying *O*-GlcNAc-modified proteins in cells. *Proc Natl Acad Sci USA*. 2003; 100:9116–9121. [PubMed: 12874386]
88. Wang Z, Pandey A, Hart GW. Dynamic interplay between *O*-linked *N*-acetylglucosaminylation and glycogen synthase kinase-3-dependent phosphorylation. *Mol Cell Proteomics*. 2007; 6:1365–1379. [PubMed: 17507370]
89. Syka JE, Coon JJ, Schroeder MJ, Shabanowitz J, Hunt DF. Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. *Proc Natl Acad Sci USA*. 2004; 101:9528–9533. [PubMed: 15210983]
90. Nandi A, et al. Global identification of *O*-GlcNAc-modified proteins. *Anal Chem*. 2006; 78:452–458. [PubMed: 16408927]
91. Shafi R, et al. The *O*-GlcNAc transferase gene resides on the X chromosome and is essential for embryonic stem cell viability and mouse ontogeny. *Proc Natl Acad Sci USA*. 2000; 97:5735–5739. [PubMed: 10801981]
92. Dauphinee SM, Ma M, Too CK. Role of *O*-linked β -*N*-acetylglucosamine modification in the subcellular distribution of α 4 phosphoprotein and Sp1 in rat lymphoma cells. *J Cell Biochem*. 2005; 96:579–588. [PubMed: 16052526]
93. Forsythe ME, et al. *Caenorhabditis elegans* ortholog of a diabetes susceptibility locus: *oga-1* (*O*-GlcNAcase) knockout impacts *O*-GlcNAc cycling, metabolism, and dauer. *Proc Natl Acad Sci USA*. 2006; 103:11952–11957. [PubMed: 16882729]
94. Lee TN, Alborn WE, Knierman MD, Konrad RJ. Alloxan is an inhibitor of *O*-GlcNAc-selective *N*-acetyl- β -D-glucosaminidase. *Biochem Biophys Res Commun*. 2006; 350:1038–1043. [PubMed: 17045574]

95. Meglasson MD, Burch PT, Berner DK, Najafi H, Matschinsky FM. Identification of glucokinase as an alloxan-sensitive glucose sensor of the pancreatic β -cell. *Diabetes*. 1986; 35:1163–1173. [PubMed: 3530846]
96. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. *Physiol Res*. 2001; 50:537–546. [PubMed: 11829314]
97. Gross BJ, Kraybill BC, Walker S. Discovery of *O*-GlcNAc transferase inhibitors. *J Am Chem Soc*. 2005; 127:14588–14589. [PubMed: 16231908]
98. Dehennaut V, et al. *O*-linked *N*-acetylglucosaminyltransferase inhibition prevents G2/M transition in *Xenopus laevis* oocytes. *J Biol Chem*. 2007; 282:12527–12536. [PubMed: 17329255]
99. Kim EJ, Perreira M, Thomas CJ, Hanover JA. An *O*-GlcNAcase-specific inhibitor and substrate engineered by the extension of the *N*-acetyl moiety. *J Am Chem Soc*. 2006; 128:4234–4235. [PubMed: 16568991]
100. Kim EJ, et al. Distinctive inhibition of *O*-GlcNAcase isoforms by an α -GlcNAc thiolsulfonate. *J Am Chem Soc*. 2007; 129:14854–14855. [PubMed: 17994748]
101. Macauley MS, Whitworth GE, Debowski AW, Chin D, Vocadlo DJ. *O*-GlcNAcase uses substrate-assisted catalysis: kinetic analysis and development of highly selective mechanism-inspired inhibitors. *J Biol Chem*. 2005; 280:25313–25322. [PubMed: 15795231]
102. Knapp S, et al. Tautomeric modification of GlcNAc-thiazoline. *Org Lett*. 2007; 9:2321–2324. [PubMed: 17508759]
103. Stubbs KA, Zhang N, Vocadlo DJ. A divergent synthesis of 2-acyl derivatives of PUGNAc yields selective inhibitors of *O*-GlcNAcase. *Org Biomol Chem*. 2006; 4:839–845. [PubMed: 16493467]
104. Dorfmueller HC, et al. GlcNAcstatin: a picomolar, selective *O*-GlcNAcase inhibitor that modulates intracellular *O*-GlcNAcylation levels. *J Am Chem Soc*. 2006; 128:16484–16485. [PubMed: 17177381]
105. Shanmugasundaram B, et al. Inhibition of *O*-GlcNAcase by a gluco-configured nagstatin and a PUGNAc-imidazole hybrid inhibitor. *Chem Commun (Camb)*. 2006; 13:4372–4374. [PubMed: 17057847]
106. Davis BG, Lloyd RC, Jones JB. Controlled site-selective glycosylation of proteins by a combined site-directed mutagenesis and chemical modification approach. *J Org Chem*. 1998; 63:9614–9615.
107. Carrillo LD, Krishnamoorthy L, Mahal LK. A cellular FRET-based sensor for β -*O*-GlcNAc, a dynamic carbohydrate modification involved in signaling. *J Am Chem Soc*. 2006; 128:14768–14769. [PubMed: 17105262]
108. Ong SE, Mittler G, Mann M. Identifying and quantifying *in vivo* methylation sites by heavy methyl SILAC. *Nat Methods*. 2004; 1:119–126. [PubMed: 15782174]
109. Zhang Z, et al. A new strategy for the synthesis of glycoproteins. *Science*. 2004; 303:371–373. [PubMed: 14726590]
110. Shin Y, et al. Fmoc-based synthesis of peptide-thioesters: application to the total chemical synthesis of a glycoprotein by native chemical ligation. *J Am Chem Soc*. 1999; 121:11684–11689.
111. Schoof H, et al. MIPS *Arabidopsis thaliana* Database (MAtdB): an integrated biological knowledge resource based on the first complete plant genome. *Nucleic Acids Res*. 2002; 30:91–93. [PubMed: 11752263]




Figure 1.

O-GlcNAc glycosylation is the addition of β-*N*-acetylglucosamine to serine or threonine residues of proteins. OGT, *O*-GlcNAc transferase; OGA, β-*N*-acetylglucosaminidase.






Figure 2.

O-GlcNAc proteome from rodent brain tissue. Approximately 31% of the known *O*-GlcNAc proteins are involved in neuronal communication and signaling, 24% participate in transcriptional regulation, and 21% are associated with cytoskeletal structures. Proteins were classified according to categories described by Schoof *et al.*¹¹¹

**Figure 3.**

Strategy for chemically tagging *O*-GlcNAc proteins. **(a)** An engineered mutant GalT enzyme transfers the UDP-ketogalactose substrate onto *O*-GlcNAc proteins. The ketone functionality is then reacted with an aminoxy biotin derivative. Tagged *O*-GlcNAc glycoproteins are then detected by chemiluminescence or isolated by streptavidin affinity chromatography. Adapted from ref. 19. **(b)** Detection of α A-crystallin using the ketogalactose-biotin tagging approach and comparison with other methods. The chemical tagging approach provides significantly improved sensitivity relative to antibodies and lectins. 0.75 μ g of α A-crystallin was used for the ketogalactose labeling method; 5 μ g of protein was used for the lectins and antibodies. **(c)** The UDP-ketogalactose substrate can be replaced with the UDP-azidogalactose substrate shown, and an azide-alkyne [3+2] cycloaddition reaction can be used to attach biotin or fluorescent dyes.

**Figure 4.**

The BEMAD strategy for mapping glycosylation sites. In this approach, the GlcNAc sugar undergoes a β -elimination reaction. Michael addition with dithiothreitol produces a sulfide adduct that is stable to MS/MS analysis.





Figure 5. Small-molecule inhibitors of *O*-GlcNAc transferase (OGT) and β -*N*-acetylglucosaminidase (OGA). **(a)** OGT inhibitors (**1–3**) identified by screening a 64,416-member library of compounds. The benzoxazolinone compound **1** inhibits OGT activity in oocytes and prevents meiotic progression. **(b)** Representative OGA inhibitors (**4–8**) with enhanced selectivity for OGA over β -hexosaminidase.

**Figure 6.**

Chemical tools for monitoring *O*-GlcNAc dynamics. **(a)** A fluorescence resonance energy transfer (FRET)-based sensor designed to detect the dynamics of *O*-GlcNAc glycosylation in living cells. Upon glycosylation, binding of the GafD lectin to the *O*-GlcNAc moiety induces a conformational change and produces a stronger FRET signal. CFP, enhanced cyan fluorescent protein; YFP, yellow fluorescent protein. **(b)** The quantitative isotopic and chemoenzymatic tagging (QUIC-Tag) approach for quantitative proteomics. Proteins from two different cell states are tagged with a ketogalactose-biotin group as shown in Figure 3a. After proteolytic digestion, the peptides are isotopically labeled and combined. The biotinylated *O*-GlcNAc peptides are captured using avidin chromatography, and quantified and sequenced by mass spectrometry. This approach enables the identification of *O*-GlcNAc proteins undergoing changes in glycosylation in response to cellular stimuli and allows for those changes to be monitored at specific sites within proteins. Adapted from ref. 19.